View Item 

Show simple item record

Economic Evaluation of the Randomized Aldactone Evaluation Study (RALES): Treatment of Patients with Severe Heart Failure
dc.contributor.authorGlick, Henry A.en_US
dc.contributor.authorOrzol, Sean Michaelen_US
dc.contributor.authorTooley, Joseph F.en_US
dc.contributor.authorRemme, Willem J.en_US
dc.contributor.authorSasayama, Shigetakeen_US
dc.contributor.authorPitt, Bertramen_US
dc.date.accessioned2006-09-11T14:59:57Z
dc.date.available2006-09-11T14:59:57Z
dc.date.issued2002-01en_US
dc.identifier.citationGlick, Henry A.; Orzol, Sean M.; Tooley, Joseph F.; Remme, Willem J.; Sasayama, Shigetake; Pitt, Bertram; (2002). "Economic Evaluation of the Randomized Aldactone Evaluation Study (RALES): Treatment of Patients with Severe Heart Failure." Cardiovascular Drugs and Therapy 16(1): 53-59. <http://hdl.handle.net/2027.42/44576>en_US
dc.identifier.issn0920-3206en_US
dc.identifier.issn1573-7241en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/44576
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12085979&dopt=citationen_US
dc.description.abstractPurpose : To use data from the Randomized Aldactone Evaluation Study (RALES) to compare clinical outcomes and costs as part of the assessment of the economic implications of spironolactone treatment of advanced heart failure.en_US
dc.format.extent100436 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers; Springer Science+Business Mediaen_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherCardiologyen_US
dc.subject.otherCongestive Heart Failureen_US
dc.subject.otherSpironolactoneen_US
dc.subject.otherRALESen_US
dc.subject.otherEconomicsen_US
dc.subject.otherCost-effectivenessen_US
dc.titleEconomic Evaluation of the Randomized Aldactone Evaluation Study (RALES): Treatment of Patients with Severe Heart Failureen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Cardiology, the, University of Michigan, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationotherDivision of General Internal Medicine and the Leonard Davis Institute of Health Economics, the University of Pennsylvania, Philadelphia, PA, 19104, USAen_US
dc.contributor.affiliationotherDivision of General Internal Medicine and the Leonard Davis Institute of Health Economics, the University of Pennsylvania, Philadelphia, PA, 19104, USAen_US
dc.contributor.affiliationotherPharmacia, Skokie, IL, USAen_US
dc.contributor.affiliationotherSTICARES Cardiovascular Research Foundation, RHOON, The Netherlandsen_US
dc.contributor.affiliationotherKyoto University, Kyoto, Japanen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid12085979en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/44576/1/10557_2004_Article_405789.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1023/A:1015371616135en_US
dc.identifier.sourceCardiovascular Drugs and Therapyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10557_2004_Article_405789.pdf
Size:
98.08KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.